Sunesis Pharmaceuticals (SNSS) Misses Q3 EPS by 8c

November 10, 2014 7:36 AM EST

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q3 EPS of ($0.25), $0.08 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $854 thousand versus the consensus estimate of $1.97 million.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings